Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 2/20 | 0.39 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.39 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.39 |
| ▸ | GRIK1 | P39086 | 8/20 | 0.34 |
| ▸ | GRIK2 | Q13002 | 7/20 | 0.34 |
| ▸ | GABRP | O00591 | 2/20 | 0.33 |
| ▸ | GABRD | O14764 | 2/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.33 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.33 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.33 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.33 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.33 |
| ▸ | GABRE | P78334 | 2/20 | 0.33 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.33 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.33 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8013132 | 0.77 | NOS3 (0.35) | GRIK1GRIK2GABRPGABRDGABRA1 | |
| SCHEMBL7558747 | 0.74 | KDM4E (0.34) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL7558750 | 0.74 | KDM4E (0.34) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL28049815 | 0.73 | — | — | |
| SCHEMBL14865058 | 0.72 | — | — | |
| SCHEMBL28236053 | 0.72 | — | — | |
| Acetic Acid SCHEMBL432873 | 0.70 | SLC1A3 (0.56) | SLC1A3SLC1A2SLC1A1GRIK1GRIK2 | |
| Acetic Acid SCHEMBL432875 | 0.70 | SLC1A3 (0.56) | SLC1A3SLC1A2SLC1A1GRIK1GRIK2 | |
| Fumaric Acid SCHEMBL28193374 | 0.70 | SLC1A3 (0.50) | SLC1A3SLC1A2SLC1A1GRIK1GRIK2 | |
| SCHEMBL2050880 | 0.69 | SLC1A2 (0.61) | SLC1A3SLC1A2SLC1A1GRIK1GRIK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1224189-B1 | CONDENSED DIHYDROQUINOLINONE DERIVATIVES FOR INHIBITING MRP1 | LILLY CO ELI (US) | 2006-01-25 | — | — | EP | disclosed |
| US-20040077675-A1 | Compounds and methods for inhibiting MRP1 | BONJOUKLIAN ROSANNE (US) | 2004-04-22 | — | — | US | disclosed |
| US-6670373-B1 | Inhibiting resistant neoplasms where the resistance is conferred by multidrug resistance protein; N-3,4,5-trimethoxyphenyl-3-(3-azidomethyl-isoxazolo(4,5-c) -1,2-dihydro-6-chloro-quinolin-2-on-1-yl)phenylacetamide | ELI LILLY AND COMPANY | 2003-12-30 | — | — | US | disclosed |
| EP-1224189-A2 | CONDENSED DIHYDROQUINOLINONE DERIVATIVES FOR INHIBITING MRP1 | ELI LILLY AND COMPANY (US) | 2002-07-24 | — | — | EP | disclosed |
| WO-2001027116-A2 | CONDENSED DIHYDROQUINOLINONE DERIVATIVES FOR INHIBITING MRP1 | ELI LILLY AND COMPANY (US) | 2001-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077675-A1 | Compounds and methods for inhibiting MRP1 | ABCC1, ABCB1, ABCB11 | SLC1A3 661/4885SLC1A2 869/4885SLC1A1 427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.